INVESTIGATIONAL PIPELINE A POWERFUL RESEARCH AND DEVELOPMENT ENGINE

Explore Regeneron's clinical pipeline

Our pipeline is powered by end-to-end research and development capabilities. The Research team discovers promising new drug compounds. From there, the Global Development team brings these investigational candidates through the full clinical development process, from trial design to study execution and lifecycle management. Our product portfolio reflects the true collaborative spirit of Regeneron. This page is intended for U.S. residents only.

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

Download Our Corporate Fact Sheet

Displaying item

SELECT PHASE:

SELECT THERAPEUTIC AREA:

SELECT MODALITY:

Biologics
Genetic Medicines

Clear All

Molecule Name

 

Therapeutic Area

Modality

Indication

Target

  •  
    ALN-APP In collaboration with Alnylam

    Therapeutic Area

    Neurology

    Modality

    Gene silencing

    Indication

    Early-onset Alzheimer’s disease

    Target

    APP

  •  
    ALN-HSD

    Therapeutic Area

    Immunology & Inflammation

    Modality

    Gene silencing

    Indication

    Nonalcoholic steatohepatitis (NASH)

    Target

    HSD17B13

  •  
    ALN-PNP In collaboration with Alnylam

    Therapeutic Area

    Immunology & Inflammation

    Modality

    Gene silencing

    Indication

    Nonalcoholic steatohepatitis (NASH)

    Target

    PNPLA3

  •  
    DB-OTO

    Therapeutic Area

    Rare Disease

    Modality

    Gene therapy

    Indication

    Hearing loss in pediatrics (Phase 1/2)

    Target

    AAV-based gene therapy

  •  
    FIANLIMAB

    Therapeutic Area

    Oncology

    Hematology

    Modality

    Monoclonal antibodies

    Indication

    Solid tumors and advanced hematologic malignancies

    Target

    LAG-3

  •  
    LINVOSELTAMAB

    Therapeutic Area

    Hematology

    Modality

    Bispecfic antibodies

    Indication

    Multiple myeloma

    Target

    BCMA and CD3

  •  
    "NEXT GENERATION" COVID ANTIBODY

    Therapeutic Area

    Infectious Disease

    Modality

    Monoclonal antibodies

    Indication

    Healthy volunteers

    Target

    SARS-CoV-2 variants

  •  
    NTLA-2001 In collaboration with Intellia

    Therapeutic Area

    Rare Disease

    Hematology

    Modality

    Gene editing

    Indication

    Transthyretin (ATTR) amyloidosis

    Target

    TTR gene knockout using CRISPR/Cas9

  •  
    ODRONEXTAMAB In collaboration with Zai Lab

    Therapeutic Area

    Oncology

    Hematology

    Modality

    Bispecfic antibodies

    Indication

    Certain B-cell malignancies

    Target

    CD20 and CD3

  •  
    REGN4336

    Therapeutic Area

    Oncology

    Modality

    Bispecfic antibodies

    Indication

    Prostate cancer

    Target

    PSMA and CD3

  •  
    REGN5093

    Therapeutic Area

    Oncology

    Modality

    Bispecfic antibodies

    Indication

    MET-altered advanced non-small cell lung cancer (NSCLC)

    Target

    Two distinct MET epitopes

  •  
    REGN5093-M114

    Therapeutic Area

    Oncology

    Modality

    Bispecfic antibodies

    Indication

    MET overexpressing advanced cancer

    Target

    Two distinct MET epitopes

  •  
    REGN5381/
    REGN9035

    Therapeutic Area

    Cardiovascular/ Metabolic

    Modality

    Monoclonal antibodies

    Indication

    Reversal agent in healthy volunteers

    Target

    NPR1/REGN5381

  •  
    REGN5459

    Therapeutic Area

    Oncology

    Hematology

    Modality

    Bispecfic antibodies

    Indication

    Transplant desensitization in patients with chronic kidney disease

    Target

    BCMA and CD3

  •  
    REGN5668

    Therapeutic Area

    Oncology

    Modality

    Bispecfic antibodies

    Indication

    Platinum-resistant ovarian cancer

    Target

    MUC16 and CD28

  •  
    REGN5678

    Therapeutic Area

    Oncology

    Modality

    Bispecfic antibodies

    Indication

    Prostate cancer

    Target

    PSMA and CD28

  •  
    REGN5837

    Therapeutic Area

    Hematology

    Modality

    Bispecfic antibodies

    Indication

    B-NHL

    Target

    CD22 and CD28

  •  
    REGN6569

    Therapeutic Area

    Oncology

    Modality

    Monoclonal antibodies

    Indication

    Solid tumors

    Target

    GITR

  •  
    REGN7075

    Therapeutic Area

    Oncology

    Modality

    Bispecfic antibodies

    Indication

    Solid tumors

    Target

    EGFR and CD28

  •  
    REGN7257

    Therapeutic Area

    Hematology

    Modality

    Monoclonal antibodies

    Indication

    Aplastic anemia

    Target

    IL2Rg

  •  
    REGN7508

    Therapeutic Area

    Hematology

    Modality

    Monoclonal antibodies

    Indication

    Thrombosis

    Target

    Factor XI

  •  
    REGN7999

    Therapeutic Area

    Hematology

    Modality

    Monoclonal antibodies

    Indication

    Transfusion dependent iron overload

    Target

    TMPRSS6

Molecule Name

 

Therapeutic Area

Modality

Indication

Target

  •  
    ALN-HSD

    Therapeutic Area

    Immunology & Inflammation

    Modality

    Gene silencing

    Indication

    Nonalcoholic steatohepatitis (NASH)

    Target

    HSD17B13

  •  
    CEMIPLIMAB

    Therapeutic Area

    Oncology

    Modality

    Monoclonal antibodies

    Indication

    Neoadjuvant cutaneous squamous cell carcinoma (CSCC); Second-line cervical cancer, ISA101b combination; First-line non-small cell lung cancer (NSCLC), BNT116 combination

    Target

    PD-1

  •  
    DUPILUMAB In collaboration with Sanofi

    Therapeutic Area

    Immunology & Inflammation

    Modality

    Monoclonal antibodies

    Indication

    Ulcerative colitis; Eosinophilic gastroenteritis (Phase 2/3)

    Target

    IL-4R alpha subunit

  •  
    FIANLIMAB

    Therapeutic Area

    Oncology

    Modality

    Monoclonal antibodies

    Indication

    First-line advanced non-small cell lung cancer (NSCLC) (Phase 2/3) (pivotal study)

    Target

    LAG-3

  •  
    LINVOSELTAMAB

    Therapeutic Area

    Oncology

    Hematology

    Modality

    Bispecfic antibodies

    Indication

    Multiple myeloma (pivotal study)

    Target

    BCMA and CD3

  •  
    MIBAVADEMAB

    Therapeutic Area

    Cardiovascular/ Metabolic

    Rare Disease

    Modality

    Monoclonal antibodies

    Indication

    Generalized lipodystrophy; Partial lipodystrophy

    Target

    Leptin receptor (LEPR)

  •  
    ODRONEXTAMAB In collaboration with Zai Lab

    Therapeutic Area

    Cardiovascular/ Metabolic

    Oncology

    Hematology

    Modality

    Bispecfic antibodies

    Indication

    B-cell non-Hodgkin lymphoma (B-NHL) (pivotal study)

    Target

    CD20 and CD3

  •  
    REGN5381/
    REGN9035

    Therapeutic Area

    Cardiovascular/ Metabolic

    Modality

    Monoclonal antibodies

    Indication

    Heart failure

    Target

    NPR1/REGN5381

  •  
    REGN9933

    Therapeutic Area

    Hematology

    Modality

    Monoclonal antibodies

    Indication

    Thrombosis

    Target

    Factor XI

  •  
    SARILUMAB In collaboration with Sanofi

    Therapeutic Area

    Immunology & Inflammation

    Modality

    Monoclonal antibodies

    Indication

    Polyarticular-course juvenile idiopathic arthritis (pcJIA) (pivotal study); systemic juvenile idiopathic arthritis (sJIA) (pivotal study)

    Target

    IL-6R

  •  
    UBAMATAMAB (REGN4018)

    Therapeutic Area

    Oncology

    Modality

    Bispecfic antibodies

    Indication

    Platinum-resistant ovarian cancer

    Target

    MUC16 and CD3

  •  
    VIDUTOLIMOD

    Therapeutic Area

    Oncology

    Modality

    Other

    Indication

    Solid tumors

    Target

    TLR9

Molecule Name

 

Therapeutic Area

Modality

Indication

Target

  •  
    ALIROCUMAB

    Therapeutic Area

    Cardiovascular/ Metabolic

    Modality

    Monoclonal antibodies

    Indication

    Hypercholesterolemia (HeFH) in pediatrics and adolescents

    Target

    PCSK9

  •  
    CEMIPLIMAB

    Therapeutic Area

    Oncology

    Modality

    Monoclonal antibodies

    Indication

    Adjuvant cutaneous squamous cell carcinoma (CSCC)

    Target

    PD-1

  •  
    DUPILUMAB In collaboration with Sanofi

    Therapeutic Area

    Immunology & Inflammation

    Modality

    Monoclonal antibodies

    Indication

    EoE in pediatrics; chronic obstructive pulmonary disease (COPD); bullous pemphigoid; chronic spontaneous urticaria (CSU); chronic pruritis of unknown origin

    Target

    IL-4R alpha subunit

  •  
    FIANLIMAB

    Therapeutic Area

    Oncology

    Modality

    Monoclonal antibodies

    Indication

    First-line metastatic melanoma; First-line adjuvant melanoma

    Target

    LAG-3

  •  
    GARETOSMAB

    Therapeutic Area

    Rare Disease

    Modality

    Monoclonal antibodies

    Indication

    Fibrodysplasia ossificans progressiva (FOP)

    Target

    Activin A

  •  
    ITEPEKIMAB In collaboration with Sanofi

    Therapeutic Area

    Immunology & Inflammation

    Modality

    Monoclonal antibodies

    Indication

    COPD

    Target

    IL-33

  •  
    POZELIMAB

    Therapeutic Area

    Cardiovascular/ Metabolic

    Rare Disease

    Hematology

    Modality

    Monoclonal antibodies

    Indication

    Myasthenia gravis, cemdisiran combination; paroxysmal nocturnal hemoglobinuria (PNH), cemdisiran combination

    Target

    C5; studied as monotherapy and in combination with cemdisiran

  •  
    REGN5713-5714-5715

    Therapeutic Area

    Immunology & Inflammation

    Modality

    Monoclonal antibodies

    Indication

    Birch allergy

    Target

    Bet v 1

No results found. Please adjust your filter selection and try again.

Technology for now
and the future

Technology is foundational to our work inventing new medicines. By combing the deep scientific expertise of our team with our proprietary VelociSuite® technologies, as well as other complementary technologies, we accelerate the way medicines are traditionally discovered and developed.

Explore Our Technology

Explore our clinical trials

The discoveries never stop as we work to help people with serious diseases. Clinical trials allow us to carefully test and collect data about investigational products before they can be approved for use. Learn more about our clinical trials or find a relevant one near you.

Find Trials
Back
to top